An Australian-developed therapy aimed at halting motor neurone disease (MND) progression and restoring function will advance to a national Phase 2 clinical trial. The protein-based therapy, called NUN-004, is designed to inhibit a receptor, EphA4, whose excessive signalling has been linked to MND.
An Australian-developed therapy aimed at halting motor neurone disease progression and restoring function will advance to a national Phase 2 clinical trial.